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Zuzana Jedlickova,1 Irina Burlakova,1 Gesine Bug,2 Herrad Baurmann,1
Rainer Schwerdtfeger,1 Michael Schleuning1This retrospective study analyzes 34 patients with severe sclerodermatous chronic graft-versus-host disease
(cGVHD) treated with inhibitors of the mammalian target of rapamycin (mTOR-I). Twelve patients received
mTOR-I as monotherapy and 22 a combination therapy. Four patients also received extracorporal photophe-
resis. mTOR-I were applied as first-line therapy (n5 15) or in refractory disease (n5 19). Drug doses were
adjusted to low therapeutical levels (3-8 ng/mL). Six and 20 patients had a complete and a partial response,
respectively, with an overall response rate of 76%. Two additional patients had stable disease. Six refractory
patients required alternative therapy. Comedication, especially steroids, could be tapered and stopped in
a significant number of patients. No difference in response was observed in everolimus- and sirolimus-
treated patients. Major adverse events possibly related to mTOR-I were hyperlipidemia and impaired wound
healing. Two patients developed thrombotic microangiopathy. Eight patients died, 5 of the nonresponders
(cGVHD; n5 3, infection; n5 2) and 3 of the responders (relapse of the underlying malignancy; n5 1, sec-
ondary malignancy; n5 1, unknown cause; n5 1). Twenty-six of the 34 patients remain alive, 18 still on ther-
apy with mTOR-I. Median follow-up for surviving patients is 723 days (range 88-1621). The overall survival at
3 years since mTOR-I is 72%. In conclusion, mTOR-I seem to be an effective and well-tolerated treatment
option for patients with sclerodermatous cGVHD.
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Chronic graft-versus-host disease (cGVHD) is the
most common problem affecting long-term survivors
of allogeneic hematopoietic cell transplantation
(HCT) [1,2]. Sclerodermatous GVHD belongs to
the most severe forms of cGVHD, with a limited
response to immunosuppressive therapy and a poor
prognosis [3]. It considerably affects the quality of the
survivors’ life because of its paralyzing consequences
including joint contractures, skin ulcers following
minor trauma, impaired wound healing, and chronicCentre for BoneMarrow and Blood StemCell Transplan-
, Deutsche Klinik fu¨r Diagnostik, Wiesbaden, Germany;
ed. Klinik III, Goethe University, Frankfurt am Main,
any.
isclosure: See Acknowledgment on page 662.
dence and reprint requests: Prof. Dr.Michael Schleuning,
e for BoneMarrow and Blood Stem Cell Transplantation,
che Klinik fu¨r Diagnostik, Aukammallee 33, 65191Wies-
, Germany (e-mail: schleuning.kmt@dkd-wiesbaden.de).
ecember 14, 2009; accepted July 27, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.07.025pain syndrome.Because of long-termhigh-dose immu-
nosuppressive therapy leading to life-threatening
infections, sclerodermatous GVHD contributes sub-
stantially to late nonrelapse mortality (NRM) after
allogeneic transplantation. Besides high-dose cortico-
steroids with multiple side effects, no effective therapy
has as yet been established. Because current therapeutic
approaches often fail, there is a need for novel immuno-
suppressive strategies for treatment of sclerodermatous
GVHD.
Sirolimus and everolimus, mammalian targets of
rapamycin inhibitors (mTOR-I), combine immuno-
suppressive properties [4] with antiproliferative effects
on fibrobroblasts and smooth muscle cells. mTOR en-
hances fibrotic overproduction of collagen and mTOR
inhibition decreases collagen mRNA stability via
a phosphatidylinositol 3-kinase-independent mecha-
nism [5]. Furthermore, sirolimus has been shown to
inhibit PDGF and fibroblast growth factor [6].
mTOR-I may therefore beneficially influence sclero-
dermatous GVHD. Antifibrotic effects of sirolimus
have been demonstrated in several in vitro and in
vivo animal models. Sirolimus inhibits hepatic fibrosis
in rats and hepatic stellate proliferation in vitro [7]. In657
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was inhibited by everolimus but not by cyclosporine
A (CsA) [8]. Additionally, a recent clinical study has re-
ported rapamycin to reduce interstitial fibrosis and
glomerulosclerosis in chronic allograft nephropathy
[9]. These data indicate that mTOR-I could provide
additional advantage for the treatment of cGVHD
with sclerotic features interfering with the process of
cutaneous or mucosal fibrosis. Moreover, recent data
indicate that rapamycin promotes the generation of
CD41CD251FoxP31 regulatory T cells. This sug-
gests that mTOR-I attenuate cGVHD also by shifting
the balance of aggressive to protective type alloim-
munity [10,11]. Here, we present a retrospective
evaluation of the use of mTOR-I (everolimus, siroli-
mus) in 34 patients with severe sclerodermatous
cGVHD following hematopoietic cell transplantation.MATERIALS AND METHODS
Study Design
In this retrospective study, treatment withmTOR-
I (everolimus or sirolimus) of 34 patients with clinical
evidence of sclerodermatous cGVHD is analyzed. Pa-
tients were treated between February 2004 and March
2009 mainly on an outpatient basis in 2 German
transplant centers (Wiesbaden, n 5 29; Frankfurt,
n 5 5). Because no approved treatment in addition to
CsA is available for treatment of sclerodermatous
cGVHD, everolimus and sirolimus were administered
off-label. The data were analyzed as of July 30, 2009.
Initially mTOR-I were used only as salvage ther-
apy in refractory patients. Later on, as positive results
became obvious, mTOR-I were also included into
front line therapy for sclerodermatous skin disease to
avoid prolonged high-dose steroid treatment with its
dismal side effects.Definitions
The diagnosis of sclerodermatous cGVHD was
based on clinical findings. Skin biopsies were not taken
on a regular basis. Whereas 33 patients developed
a cutaneous form of cGVHD with profound sclerotic
features, 1 patient suffered from severe dysphagia be-
cause of stenosis of the upper third of the esophagus ne-
cessitating multiple invasive endoscopic interventions.
All patients suffered from a deep, nonmobile (hide-
bound) scleroderma, meeting the definition of skin
score 3 according to the NIH-Consensus Criteria for
clinical trials in cGVHD [12].With skin score 3 (organ
scoring) all patients fulfilled the criteria for a severe
grade of cGVHD (global scoring). cGVHD was
defined as progressive, if acute GVHD (aGVHD)
evolved into cGVHD. GVHD was defined as quiescent
if aGVHD had resolved and de novo in cases withouthistory of aGVHD. For technical reasons, patients
with de novo and quiescent cGVHD were combined
for this analysis. Post-donor lymphocyte infusions
(DLIs), cGVHD occurred following immunotherapy
with DLIs and postretransplant cGVHD occurred after
second transplantation for relapse.
The clinical evaluation of sclerodermatous
cGVHD was performed monthly during the first 12
months of treatment and subsequently 4 times per
year at least. Response to therapy was defined as com-
plete remission (CR) if no evidence for scleroderma-
tous GVHD lesions was observed during clinical
examination. Partial remission (PR) was defined as
any improvement of sclerodermatous features or of
range of motion without CR. Stable disease was
defined as no change in sclerodermatous GVHD.
Nonresponsive patients demonstrated progressive
sclerodermatous GVHD necessitating a change of
the immunosuppressive regimen.
Treatment Regimen
Sirolimus and everolimus were administered orally
twice a day adjusted to maintain low therapeutic
trough whole-blood levels of 3-8 ng/mL. Drug levels
were measured weekly until a consistent therapeutic
level was achieved, and every 2-3 weeks thereafter.
Whereas 12 patients were treated with mTOR-I as
a monotherapy, most of the patients received a combi-
nation of immunosuppressants. The dosage of myco-
phenolate mofetil was 1 g twice a day. Steroids were
given at 1 mg per kg a day and were tapered as soon
as clinically possible. Four patients received an addi-
tional therapy with extracorporal photopheresis.
Three patients received other additional immunomod-
ulatory drugs (retinoid n 5 1, thalidomide n 5 1, and
CsA n 5 1). Patients received prophylactic antiviral
therapy against herpes virus infections and prophylaxis
against Pneumocystis carinii and Toxoplasma gondii.
Patients with long-term steroid medication received
antimycotic prophylaxis.
Statistical Analysis
The main endpoints were clinical response in scle-
rodermatous cGVHD and overall survival (OS). Sec-
ondary endpoints included the ability to discontinue
immunosuppressive comedications, implicating also
response of other organ manifestations of cGVHD.
Finally, the comparison of clinical outcome of everoli-
mus versus sirolimus-treated patients and mTOR-I
attributable toxicities were assessed.
OS was calculated according to the method of Ka-
plan and Meier [13]. It was defined as the time from
mTOR-I initiation to death from any cause. The
differences were compared using the Log-Rank test.
Descriptive statistics were used when applicable, and
for comparative analyses Fisher exact test was used.
Table 1. Patients Characteristics
No. of Pts %
Variable 34 100
Age at SCT (years)
Median (range) 43 (18- 64)
Sex
Male 17 50.0
Female 17 50.0
Donor type, HLA- compatibility
Matched related 16 47.1
Matched unrelated 13 38.2
Mismatched unrelated 5 14.7
Stem cell source
Bone marrow 11 32.4
Peripheral blood 23 67.6
Indication for SCT 0.0
AML 12 35.3
MDS 2 5.9
ALL 8 23.5
BAL* 1 2.9
CML 3 8.8
NHL 2 5.9
PMF 3 8.8
T-PLL 1 2.9
MM 2 5.9
SCT indicates stem cell transplantation; AML, acute myelogenous leuke-
mia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leuke-
mia; BAL, biphenotypical acute leukemia; CML, chronic myelogenous
leukemia; MM, multiple myeloma; NHL, non-Hodgkin leukemia; T-PLL,
T-cell prolymphocytic leukemia; PMF, primary myelofibrosis.
Table 2. Chronic GVHD Profile
Variable N 5 34 % 100
GVHD onset profile
Progressive 5 14.7
de novo/quiescent 13 38.2
Post-DLI 10 29.4
Post-retransplant 6 17.6
Platelets (109/L)
<100 3 8.8
>100 31 91.2
Prior immunosuppressive therapy
None 15 44.1
1 line 12 35.3
>1 line 7 20.6
History of acute GVHD
No 8 23.5
Grade I and II 19 55.9
Grade III and IV 7 20.6
Extracutaneous GVHD involvement
Oral mucosa 19 55.9
Eyes 10 29.4
Liver 10 29.4
Lung 6 17.6
Gastrointestinal 6 17.6
Muscular 6 17.6
Polyserositis 1 2.9
GVHD indicates graft-versus-host disease; DLI, donor leukocyte
infusion.
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software package (SPSS Inc., Chicago, IL, USA). All
P-values are 2-sided. A P-value\.05 was considered
statistically significant.Table 3. Immunosuppressive Therapy
Variable N 5 34 % 100
mTOR-I used
Everolimus 21 61.8
Sirolimus 13 38.2
Regimens containing mTOR-I used
mTOR-I monotherapy 12 35.3
mTOR-I in combination* 22 64.7
MTOR-I+steroids 11 32.4
MTOR-I+steroids+MMF 4 11.8
MTOR-I+steroids+ECP 4 11.8
MTOR-I+MMF 3 8.8
MMF indicates mycophenolate mofetil; mTOR-I, inhibitors of the
mammalian target of rapamycin; ECF, Extracorporal photopheresis.
*Additional immunsuppressive drugs were used in 3 pts (retinoid n5 1,
thalidomide n 5 1, and cyclosporine A n 5 1).RESULTS
Patient Characteristics
Characteristics of all patients are summarized in
Table 1. There were 17 females and 17 males, median
age at transplantation was 43 years (range: 18-64). The
stem cell sources were peripheral stem cells in 23
patients (68%) and BM in 11 patients (32%). In 16
cases (48%), the donor was a matched sibling. Eigh-
teen patients (53%) were grafted from an unrelated do-
nor, 5 of them receiving grafts fromHLA-mismatched
donors. Six patients received a second transplantation
because of a hematologic malignancy relapse—in all
these cases peripheral blood stem cells were used.
Most patients had had a history of aGVHD, grades
1-2 (n 5 19, 55%). 10 patients (44%) with high-risk
malignancies were treated with DLIs. Whereas 2
patients received adjuvant DLIs, in 8 patients DLIs
were applied because of a relapse of malignant disease.
The median dose of CD 31 lymphocytes applied
per kg body weight of the host was 6  106 (range:
1  105-6.5  107). While in most patients clinical
signs of chronic GVDHwere present in several organs,
four patients suffered from isolated skin scleroderma-
tous GVHD. In three patients, chronic GVHD wasassociated with thrombocytopenia \100  109/L.
Onset profiles and extracutaneous involvement of
chronic GvHD are summarized in Table 2. Median
time from transplantation to initial diagnosis of
chronic GVHD was 459 days, (range 161-1091). In
15 patients (44%), mTOR-I were administered as
a first-line treatment of sclerodermatous GVHD,
mostly in combination with steroids. Twelve patients
(35%) received the mTOR-I as a secondary therapy
and 7 patients (20%) failed at least 2 treatment lines
prior to mTOR-I. Details of the immunosuppressive
therapy are outlined in Table 3. The median time for
duration of mTOR-I therapy for monotherapy group
and combined therapy group were 824 days (range:
Table 4. Response
No. of pts. %
Variable 34 100
Overall response 26 76.5
Complete remission 6 17.6
Partial remission 20 58.8
No change 2 5.9
Progress 6 17.6
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median time for follow-up for monotherapy group
and combined therapy group were 1085 days (range:
144-1621) and 482 days (range: 88-1418), respectively.Response to Therapy
Six (18%) and 20 patients (59%) had a complete
and a partial response, respectively, with an overall
response rate of 76%. In 2 patients, sclerodermatous
changes stayed without progression and reduction of
immunosuppressive comediation was possible without
disease flair. Six patients (18%) were refractory dis-
playing progress of the disease and the mTOR-I ther-
apy was discontinued (Table 4). Twelve of 22 patients
stopped additional immunosuppressive therapy. No
significant differences in response were observed in
everolimus- and sirolimus-treated patients (Table 5).
Possibly because of the small patient numbers the
onset profile of GVHD had no significant influence
on clinical response rate. No significant differences
in response were seen by stem cell source, donor
type, histocompatibility or number of prior immuno-
suppression lines. Median time to PR was 3 months
(range: 2-25 months) and median time to CR was 28
months (range: 7-36 months). Average time to discon-
tinuation because of progress was 153 days (range:
37-514). In the monotherapy group median time to
PR was 66 days (range: 63-235 days), median time to
CR was 223 days (range: 210-730 days). Only 2
patients progressed after 141 or 144 days. In the group
of combined therapy median time to PR was 91 days
(range: 27-389 days), median time to progress was
190 days (range: 37-514 days). Two patients reached
complete remission after 470 and 1083 days.Table 5. First Line versus Salvage Therapy
CR PR NC NR Total
Initial therapy 4 8 1 2 15
One or more prior therapies 2 12 1 4 19
Monotherapy vs. combined therapy
mTOR-I monotherapy 4 6 0 2 12
Combined therapy 2 14 2 4 22
mTOR-I used and response
Everolimus 4 13 1 5 23
Sirolimus 2 7 1 1 11
CR indicates complete response; PR, partial response; NC, no change/
stable disease; NR no response/progress.In the patient with esophageal sclerosis, everoli-
mus was started after a dilatation procedure was com-
plicated by rupture. After 2 months of everolimus
monotherapy, the patient improved significantly and
resolved all symptoms within 6 months without any
further dilatation attempts. After 3.5 years, everolimus
was discontinued and the patient remained in CR 2
years after mTOR-I discontinuation.
Steroid-Sparing Effects
Nineteen patients were receiving steroids at the
beginning of mTOR-I treatment. Average daily pred-
nisolone dose at the beginning of the treatment with
mTOR-I was 40 mg (range: 5-65 mg). Three months
after onset of mTOR-I therapy 5 patients (26%)
stopped steroid comedication. Seven patients (36%)
had a 50% or greater reduction in the total daily
dose of corticosteroids and 5 of them had a daily
dose of 10 mg or less. At the end of follow-up, 10 of
19 patients (52%) completely discontinued steroids.
Survival
After a median follow-up time of 451 days (range:
62-1480) since initiation of mTOR-I, there were 8
deaths, 5 of which were attributed to cGVHD and
infectious complications in nonresponders. Three of
the responders died, 1 patient of secondarymalignancy
(nonsmall-cell lung carcinoma), 1 of relapse of his
underlying disease, 1 of unknown reason. Projected
OS at 3 years was 72%. No significant differences in
survival were observed in everolimus- and sirolimus-
treated patients (Figure 1).
At the time of analysis, 26 of the 34 patients
remained alive, 18 of them still on therapy with
mTOR-I. Median follow up of surviving patients was
723 days (range: 88-1621).Figure 1. Kaplan-Meier estimates of overall survival since initiation of
mTOR-I therapy comparing sirolimus and everolimus.
Table 6. Toxicity
Variable No. of pts %
Infections 14 41.2
Coagulopathy 9 26.5
Hyperlipidemia 7 20.6
Impaired wound healing 5 14.7
TMA 2 5.9
Thrombosis 3 8.8
TMA indicates thrombotic microangiopathy.
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The duration of the therapy with mTOR-I for the
whole group was 27 to 1621 days (median 429 days).
The therapy with mTOR-I was discontinued in 10
patients. Two patients discontinued mTOR-I therapy
after achieving complete remission of sclerodermatous
GVHD. The toxicity of mTor-I therapy is summa-
rized in Table 6. In 5 patients, mTOR-I were stopped
because of ulcerous skin lesions, as mTOR-I may
interfere with wound healing processes [14]. One
patient terminated therapy because of a relapse of the
underlying hematologic malignancy and 2 patients
because of drug intolerance. Hyperlipidemia [15]
occurred in 7 patients (21%) and in 2 cases it required
therapeutical intervention. There was no correlation
between hyperlipidemia and mTOR-I trough levels.
Fourteen patients (41%) suffered from infections—8
of them had bacterial infections of the respiratory sys-
tem and 2 patients had documented clinical diagnosis
of fungal pneumonia. Severe generalized infections
caused by cutaneous multiresistent bacteria colonizing
skin ulcers were present in 4 nonresponders. Two
varicella zoster virus reactivations occurred, 1 of
them as therapy resistant abdominal zoster infection
with a lethal course. Thrombocytopenia associated
with thrombotic microangiopathy (TMA) occurred
in 2 patients and it correlated with high tough levels
of mTOR-I. No other cytopenias have been observed.
Both cases of TMA resolved after dose reduction of
mTOR-I. One patient developed squamous cell skin
carcinoma 2 months after initiation of m-TOR ther-
apy requiring surgical intervention. Three patients
treated with mTOR-I and prednisolone developed
deep venous thrombosis. These were unprovoked
thromboses without association with TMA and
patients had not received any other pro-thrombotic
drugs (besides steroids). Plasmatic haemostasis
markers were monitored during therapy and in 9 pa-
tients (27%), activated hemostatic system (shortened
prothrombine time) was observed, suggesting some
procoagulatory activity. Therefore, patients treated
with the combination regimen of mTOR-I and corti-
costeroids received antithrombotic prophylaxis (aspi-
rin, low-molecular heparin).
Only 1 patient with multiple myeloma relapsed
during the treatment with mTOR-I. No nephrotoxi-
city and no interstitial pneumonitis were observed.DISCUSSION
cGVHD with sclerodermatous features is a severe
complication of allogeneic transplantation, with a sub-
stantial impact on the quality of life and survival, still
lacking an optimal therapeutic strategy. This retro-
spective clinical study provides evidence that
mTOR-I are efficient and reasonably safe therapeutic
agents for the treatment of sclerodermatous cGVHD.
We analyzed 34 patients having severe cGVHD
with sclerodermatous manifestations. We observed
significant clinical responses in 26 patients (76%), 20
of them had PR and 6 had CR of sclerodermatous
cGVHD. A significant number of patients tapered
off their immunosuppressive comedication, especially
steroids. No significant difference in response was ob-
served in everolimus- and sirolimus-treated patients.
The projected survival after 3 years since initiation of
mTOR-I of 72% seems rather high in this cohort of
severe cGVHD patients with high-risk malignancies.
As scleroderma belongs to the rather rare manifes-
tations of cGVHD [3] only limited data are available
concerning its therapy. To our knowledge, this is
one of the largest retrospective studies on therapeuti-
cal approaches to severe sclerodermatous GVHD.
Our results are in agreement with previous observa-
tions on smaller series of patients with significant
improvement of scleroderma following therapy with
mTOR-I, mostly in combination with calcineurin
inhibitors (CNI) [16,17].
Intriguingly, our data showed the efficacy of
mTOR-I therapy even in the absence of CNI, as all
but 1 patient were treated with a CNI-free immuno-
suppressive regimen. Compared with a study describ-
ing the treatment of cGVHD with sirolimus in
combination with tacrolimus and corticosteroids
[16], we achieved similar response rates (76% in our
study versus 73% reported by Couriel et al.) and
a more favorable toxicity profile. So far mTOR-I
have been applied as a salvage therapy of steroid-
resistant sclerotic GVHD. In contrast, in our study,
mTOR-I were administered as a first-line therapy in
15 patients (44%), mostly in combination with ste-
roids. This approach may allow for a faster tapering
of steroids, so that the time of exposure to high-dose
steroids can be shortened and steroid-associated side
effects diminished.
Renal dysfunction and TMA are common toxic-
ities attributable to coadministration of mTOR-I
with CNI [18,19]. Importantly, in our study, we
observed no nephrotoxicity, and TMA was rare
(5.9%), correlating with high trough levels of
mTOR-I. Generally, if low therapeutical trough levels
were maintained, toxicities associated with mTOR-I
therapy were moderate. Because mTOR-I could
possibly interfere with wound healing [14,20], they
should be used with caution in patients with
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ulcerous lesions, other therapeutic modalities should
be chosen (eg, extracorporal photopheresis). mTOR-
I seem to enhance plasmatic coagulation, as suggested
by significant shortening of prothrombine time in 9
patients. Therefore, monitoring of plasmatic hemosta-
sis markers might be advisable during mTOR-I
therapy. The involvement of mTOR in coagulation
signaling cascades has as yet not been reported.
Thus, further experimental studies are needed to clar-
ify the possible role of mTOR-dependent downstream
pathways in hemostasis. Hyperlipidemia was frequent,
but seldom required therapeutic intervention.
Of interest, all but 1 patient remained in complete
remission of their hematologic malignancy while on
mTOR-I therapy, despite high-risk conditions, as 13
patients (38%) had already relapsed after allogeneic
transplantation. This may be because of a synergic im-
pact of the graft versus malignancy effect combined
with antitumoral activity of mTOR-I [21,22].
Extracorporal photopheresis (ECP) is increasingly
recognized as another alternative modality in the treat-
ment of steroid-refractory cGVHD [23]. Several stud-
ies have reported high response rates in patients with
skin involvement, including cases with scleroderma-
tousGVHD [24] (14 of 21 patients responded). In a re-
cent randomized multicenter trial the addition of ECP
to standard treatment seemed to bemore effective even
in sclerodermatous skin disease with a 40% response
rate at 12 treatment weeks [25]. Its efficacy in sclero-
dermatous skin disease has also been questioned,
however [26].
Furthermore, 2 recent small clinical studies have
suggested the tyrosine kinase inhibitor imatinib mesy-
late to be active in the treatment of steroid-refractory
sclerodermatous GVHD [27,28] via inhibition of
fibroblast activity and transforming growth factor-
beta (TGF-b). Response rates of 50% to 79% have
been reported. However, especially in higher doses
up to 30% of patients did not tolerate imatinib and
stopped treatment. In addition, Skert et al. [3] have
reported responses to the therapy with methotrexate,
especially in case of limited scleroderma.
Our data indicate that mTOR-I are a promising
therapeutical tool in the management of scleroderma-
tous GVHD. It remains to be determined, whether
their use in combination with other therapeutical
options may lead to a more positive outcome because
of potential synergic effects. Especially in refractory
cases, combining mTOR-I and ECP treatment might
be an effective method according to our preliminary
clinical experience.
Because sclerodermatous GVHD shares many
clinical characteristics with systemic sclerosis [29]
and both are associated with similar pathogenetic
mechanisms of autoimmunity and skin fibrosis [3],
mTOR-I might even be efficient in the managementof systemic sclerosis, as it has been stated in a recent
case study [30].
In summary, this retrospective analysis provides
evidence that mTOR-I may be effective in controlling
sclerodermatous cGVHD with an acceptable safety
profile. Prospective, controlled trials are warranted
to assess the impact of mTOR-I on OS and quality
of life compared to alternative therapeutical ap-
proaches in patients with sclerodermatous cGVHD.ACKNOWLEDGMENT
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